Protective effect and mechanism of TREM2 in Parkinson’s disease with cognitive impairment
Objective: this study explored whether TREM2 plays a protective role in PD with cognitive impairment by promoting the activation of DAM. Background: The latest research…Development of therapeutic substances for the disassembly of α-synuclein aggregates as disease-modifying treatment of synucleinopathies
Objective: Development of high-affinity ligands to α-synuclein (α-syn) for a therapeutic approach aiming for the disassembly of α-syn aggregates as a disease-modifying treatment of synucleinopathies.…Distinct characteristics of gut microbiome in patients with Parkinson’s disease according to the presence of premotor REM sleep behavior disorders
Objective: We aimed to investigate whether the composition and function of gut microbiome obtained from shotgun metagenomic sequencing are different between Parkinson’s disease (PD) patients…A multicenter, matched case-control study of alpha-synuclein accumulation in the gastrointestinal tract of Parkinson’s disease
Objective: 1) To determine the possibility as a pathologic biomarker of alpha-synuclein (AS) accumulation in the gastrointestinal (GI) tract in patients with Parkinson’s disease (PD) and…Small Molecule Inhibitors for Precise Inhibition of α-Synuclein Oligomer Generation in Parkinson’s Disease (PD)
Objective: To develop small molecule therapeutics for PD that inhibit production of toxic α-synuclein oligomers and reduce aggregate formation, targeting the molecular mechanisms at the…Recruiting people at risk of Parkinson’s disease: comparative data from PPMI Online and HeBA Kassel
Objective: To compare a US- and Germany-based staged screening process to identify people at risk of developing Parkinson’s disease (PD). Background: The Parkinson’s Progression Marker…Longitudinal CSF measurements of alpha-synuclein, amyloid beta and tau in Parkinson disease
Objective: To evaluate whether cerebrospinal fluid (CSF) levels of alpha synuclein (Asyn), amyloid beta (Aβ) and tau change with disease progression and to evaluate whether…Alzheimer’s Disease Co-pathology and its Influence on Biofluid Biomarkers in Autopsied Subjects from the PPMI Study
Objective: To examine the relationship between biofluid biomarkers and post-mortem pathological findings in autopsied subjects from the Parkinson’s Progression Marker Initiative (PPMI). Background: The PPMI…Analysis of α-Synuclein Seed Amplification Assay in Carriers of GBA and LRRK2 Pathogenic Variants
Objective: To assess α-synuclein seed amplification assay (αS-SAA) in cerebrospinal fluid (CSF) from a cohort of PD patients and non-manifesting carriers (NMCs) of pathogenic GBA…Synaptic density and α-synuclein oligomers in skin biopsies: differences between idiopathic and GBA-linked Parkinson’s disease
Objective: To compare α-synuclein oligomers and synaptic density (SD) in skin biopsies from PD and GBA-PD. Background: Previous research [1] reported α-synuclein oligomers within synaptic terminals of autonomic fibers in…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 60
- Next Page »